Health-related quality of life and continuation rate on first-line anti-tumour necrosis factor therapy among rheumatoid arthritis patients from the Australian Rheumatology Association Database

Rheumatology

Volumn 50, Issue 1, 2011, Pages 166-175

  Staples, Margaret P ^a   March, Lyn ^b,c   Lassere, Marissa ^d,e   Reid, Chris ^a   Buchbinder, Rachelle ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ROYAL NORTH SHORE HOSPITAL   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e ST GEORGE HOSPITAL   (Australia)

Author keywords

Anti tumour necrosis factor drugs; Biologic disease modifying anti rheumatic drugs; Health related quality of life; Registry; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; PREDNISOLONE; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ARTICLE; ASSESSMENT OF QUALITY OF LIFE; DATA COLLECTION METHOD; DISEASE DURATION; EUROPEAN QUALITY OF LIFE 5 DIMENSIONS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; SELF REPORT; SHORT FORM 36;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUSTRALIA; BIOLOGICAL PRODUCTS; CLINICAL TRIALS AS TOPIC; DATABASES, FACTUAL; FEMALE; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; REGISTRIES; SEVERITY OF ILLNESS INDEX; STATISTICS AS TOPIC; TUMOR NECROSIS FACTORS;

EID: 79951689695     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq322     Document Type: Article

References (47)

1. Nurmohamed MT, Dijkmans BA. Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis. Drugs 2005;65:661-94.
2. Strand V, Scott D, Emery P et al. Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis. J Rheumatol 2005;32:590-601.
3. van der Kooij SM, de Vries-Bouwstra JK, GoekoopRuiterman YP et al. Patient-reported outcomes in a randomized trial comparing four different treatment strategies in recent-onset rheumatoid arthritis. Arthritis Rheum 2009; 61:4-12.
4. Schett G, Stach C, Zwerina J, Voll R, Manger B. How antirheumatic drugs protect joints from damage in rheumatoid arthritis. Arthritis Rheum 2008;58:2936-48.
5. Schwartzman S, Fleischmann R, Morgan GJ Jr. Do anti-TNF agents have equal efficacy in patients with rheumatoid arthritis? Arthritis Res Ther 2004;6(Suppl. 2): S3-11.
6. Rubbert-Roth A, Finckh A. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res Ther 2009;11(Suppl. 1):S1.
7. Briggs A, Buchbinder R, Lassere M, Reid C, March L. Baseline comorbidities in an Australian population-based cohort of rheumatoid arthritis patients receiving biological therapy: data from the Australian Rheumatology Association Database (ARAD). Int J Rheum 2009; Article ID 861481.
8. Buchbinder R, March L, Lassere M et al. Effect of treatment with biological agents for arthritis in Australia: the Australian Rheumatology Association Database. Intern Med J 2007;37:591-600.
9. Schiff M, Keiserman M, Codding C et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008;67:1096-103.
10. Han C, Smolen JS, Kavanaugh A et al. The impact of infliximab treatment on quality of life in patients with inflammatory rheumatic diseases. Arthritis Res Ther 2007; 9:R103.
11. van Riel PL, Freundlich B, MacPeek D et al. Patient-reported health outcomes in a trial of etanercept monotherapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis: the ADORE trial. Ann Rheum Dis 2008;67:1104-10.
12. Russell AS. Quality-of-life assessment in rheumatoid arthritis [Review]. Pharmacoeconomics 2008;26:831-46.
13. Weinblatt ME, Keystone EC, Furst DE et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35-45.
14. van den Hout WB, Goekoop-Ruiterman YP, Allaart CF et al. Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2009;61:291-9.
15. Kimel M, Cifaldi M, Chen N, Revicki D. Adalimumab plus methotrexate improved SF-36 scores and reduced the effect of rheumatoid arthritis (RA) on work activity for patients with early RA. J Rheumatol 2008;35:206-15.
16. Maini RN, Breedveld FC, Kalden JR et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004;50:1051-65.
17. Kievit W, Adang EM, Fransen J et al. The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data. Ann Rheum Dis 2008; 67:1229-34.
18. Heiberg MS, Koldingsnes W, Mikkelsen K et al. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum 2008;59:234-40.
19. Hyrich KL, Deighton C, Watson KD, Symmons DP, Lunt M. Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity. Rheumatology 2009;48: 1323-7.
20. Lassere M, Johnson K, van Santen S et al. Generic patient self-report and investigator report instruments of therapeutic safety and tolerability. J Rheumatol 2005; 32:2033-6.
21. Fries J, Spitz P, Kraines G, Holman H. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23: 137-45.
22. Wells G, Tugwell P, Kraag G, Baker P, Groh J, Redelmeier D. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol 1993;20:557-60.
23. Hawthorne G, Osborne RH, Taylor A, Sansoni J. The SF36 Version 2: critical analyses of population weights, scoring algorithms and population norms. Qual Life Res 2007;16: 661-73.
24. Kosinski M, Zhao SZ, Dedhiya S, Osterhaus JT, Ware JE Jr. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 2000;43:1478-87.
25. Hawthorne G, Richardson J, Osborne R. The Assessment of Quality of Life (AQoL) instrument: a psychometric measure of health related quality of life. Qual Life Res 1999;8:209-24.
26. Hawthorne G, Osborne R. Population norms and meaningful differences for the Assessment of Quality of Life (AQoL) measure. Aust NZ J Public Health 2005;29: 136-42.
27. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001;33:337-43.
28. Walters SJ, Brazier JE. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res 2005;14:1523-32.
29. Groessl EJ, Ganiats TG, Sarkin AJ. Sociodemographic differences in quality of life in rheumatoid arthritis. Pharmacoeconomics 2006;24:109-21.
30. Australian Bureau of Statistics, ed. 1995 National Health Survey. SF-36 population norms Australia. Canberra Australia: ABS, 1997.
31. Kind P, Hardman G, Macran S. UK population norms for EQ-5D. Discussion paper 172. York: Centre for Health Economics 1999.
32. Lassere M, Edmonds J. J. Psychological measures: practical issues in observational studies and clinical monitoring. J Rheumatol 1997;24:1004-7.
33. Alishiri GH, Bayat N, Fathi Ashtiani A, Tavallaii SA, Assari S, Moharamzad Y. Logistic regression models for predicting physical and mental health-related quality of life in rheumatoid arthritis patients. Mod Rheumatol 2008;18: 601-8.
34. Bendtsen P, Hornquist JO. Change and status in quality of life in patients with rheumatoid arthritis. Qual Life Res 1992;1:296-305.
35. Pollard L, Choy EH, Scott DL. The consequences of rheumatoid arthritis: quality of life measures in the individual patient. Clin Exp Rheumatol 2005;23(5 Suppl. 39): S43-52.
36. Rupp I, Boshuizen HC, Roorda LD, Dinant HJ, Jacobi CE, van den Bos G. Course of patient-reported health outcomes in rheumatoid arthritis: comparison of longitudinal and cross-sectional approaches. J Rheumatol 2006;33: 228-33.
37. Lassere M, Wells G, Tugwell P, Edmonds J. Percentile curve reference charts of physical function: rheumatoid arthritis population. J Rheumatol 1995;22: 1241-6.
38. Kojima M, Kojima T, Ishiguro N et al. Psychosocial factors, disease status, and quality of life in patients with rheumatoid arthritis. J Psychosom Res 2009;67: 425-31.
39. Salaffi F, Carotti M, Gasparini S, Intorcia M, Grassi W. The health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a comparison with a selected sample of healthy people. Health Qual Life Outcomes 2009;7:25.
40. Tugwell P, Idzerda L, Wells GA. Generic quality-of-life assessment in rheumatoid arthritis. Am J Manag Care 2007;13(Suppl. 9):S224-36.
41. Edmonds J, Lassere M. Rheumatoid arthritis: time for trials of therapeutic targets. J Rheumatol 2002;29: 2041-4.
42. Grigor C, Capell H, Stirling A et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004;364:263-9.
43. Yocum D. Effective use of TNF antagonists. Arthritis Res Ther 2004;6(Suppl. 2):S24-30.
44. Gomez-Reino JJ, Carmona L. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther 2006;8:R29.
45. Wluka A, Buchbinder R, Mylvaganam A et al. Longterm methotrexate use in rheumatoid arthritis: 12 year followup of 460 patients treated in community practice. J Rheumatol 2000;27:1864-71.
46. Singh JA, Christensen R, Wells GA et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev 2009; 4:CD007848.
47. Breedveld FC, Weisman MH, Kavanaugh AF et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006; 54:26-37.